# Addiction Medicine Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elvis Presley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML003-SYN-TD
- Date: 1974-07-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Eberhardt-Mensah, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Coleman Ashby-Nakagawa, MD

## Reason for consultation

Long-term prescription opioids and benzodiazepines from five prescribers, with fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, in a 39-year-old touring singer who wants to change how he takes his medicines. Please assess for substance use disorders and advise on medication for opioid use disorder and a safe benzodiazepine plan. **S**

## History

Mr. Presley, a 39-year-old singer, is seen at the request of Dr. Ashby-Nakagawa. He began opioids about five years ago for back and neck pain from performing, and benzodiazepines for sleep after late shows. Over time he took more than prescribed, found more than one prescriber, and felt sick and craved them when he ran short; a hospital stay some years ago withdrew him from opioids, and he restarted within months. He has never injected or used illicit drugs and does not drink. For the past week he has taken only this clinic's prescriptions. He last took hydromorphone about 18 hours ago and oxycodone about 20 hours ago, as planned, and is in mild to moderate withdrawal. He took diazepam and alprazolam last night. He has a Las Vegas engagement in five weeks and a tour after it and wants to start treatment now. **S**

## Examination

| System | Finding |
|---|---|
| General | Restless, yawning; blood pressure 146/94, pulse 102, temperature 37.0 °C |
| Eyes | Pupils 5 mm and reactive; lacrimation |
| Skin | Piloerection; sweating; no injection marks |
| Neurological | Mild tremor of the outstretched hands; alert and oriented |

BP 146/94 mmHg; pulse 102 bpm; respirations 18/min; temperature 37 °C; oxygen saturation 96% on room air; weight 108.6 kg; BMI 32.4 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Ashby-Nakagawa's intake note and the prescription drug monitoring program report (five prescribers, three pharmacies, about 145 MME a day with two benzodiazepines). DAST-10 7, AUDIT-C 0, PHQ-9 8, GAD-7 9. The structured safety assessment. Liver tests mildly raised; ECG normal with a QTc of 436 ms. In-laboratory polysomnography three days ago: apnea-hypopnea index 26 an hour, central apnea index 4. Point-of-care urine test today: hydromorphone, oxycodone and benzodiazepines; no fentanyl. COWS 12. 

## Assessment

1. **Opioid use disorder, severe** (F11.20). Seven DSM-5-TR criteria: larger amounts than intended, unsuccessful efforts to cut down, much time spent obtaining prescriptions, craving, continued use despite physical problems, tolerance and withdrawal, which count here because the opioids were not taken as prescribed. Buprenorphine lowers the risk of overdose and death and fits a touring life better than methadone, which needs daily clinic dosing. A standard start is suitable because his opioids are short-acting and he is already in moderate withdrawal; a low-dose start would be chosen for someone who cannot tolerate withdrawal or is on methadone. **S**
2. **Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate** (F13.20). Five criteria, including withdrawal. Abrupt stopping risks seizures. The 1973 joint guideline allows a switch to a single longer-acting benzodiazepine, advises against tapering during other major changes, and suggests reductions of about 5 to 10% every two to four weeks, adjusted to symptoms. Taking a benzodiazepine is not a reason to withhold buprenorphine, but the combination raises the risk of sedation and slowed breathing, especially with sleep apnea. **S**
3. **Obstructive sleep apnea** (G47.33). Moderate obstructive sleep apnea with a small central component; CPAP is important while he takes buprenorphine and diazepam, and no additional night sedative should be used. **S**

## Recommendations

1. Start buprenorphine with naloxone in the office today at COWS 12: 4 mg, then 4 mg after an hour if withdrawal persists; 16 mg daily from tomorrow, adjusted up to 24 mg for cravings or withdrawal.
2. Stop hydromorphone and oxycodone today and take back the remaining tablets; no full-agonist opioid from any prescriber.
3. Combine diazepam and alprazolam into diazepam 10 mg four times daily (40 mg a day); no taper step until buprenorphine has been stable for two to three weeks, then reduce by about 10% every four weeks or so, pausing for engagements, illness or withdrawal symptoms; CBT for anxiety and insomnia.
4. Naloxone at home and in the tour bag, with people around him trained; no alcohol, no other sedatives, and CPAP every night.
5. A single prescriber and one named pharmacy, a monitoring program check before each prescription, seven-day supplies for the first month then two weeks, and a urine drug test at the start, about a month later and when doses change.
6. Weekly contact for the first month, counseling, and safety review at every visit.
7. For engagements and tours: no medication change in the week before, prescriptions sent to one named pharmacy where he will be, weekly video visits, and a written plan for missed doses.
8. For acute pain: continue buprenorphine and split the dose, add an NSAID or other non-opioid treatment, and call this clinic before any other prescriber gives an opioid.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Ashby-Nakagawa, who saw him the same day. The diagnoses and the plan were explained to Mr. Presley without blame; he asked whether buprenorphine would affect his voice or his energy on stage, was told that it should not once the dose is steady, and chose to start today. **S**

## Follow-up

Addiction medicine will see him again in three months or sooner if cravings return or the taper stalls; Dr. Ashby-Nakagawa prescribes and follows him, with weekly contact in the first month. **S**

## Guideline basis

- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (J Addict Med 2020;14(2S Suppl 1):1-91)
- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019), American Academy of Sleep Medicine (J Clin Sleep Med 2019;15(2):335-343)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
